Business Wire - June 19,2002
Under the collaborative agreement, Regma will sponsor research at the Institut Pasteur de Lille in the development of therapies in the response to the growing problem of antibiotic resistance, more particularly against Mycobacterium tuberculosis (Mtb). Dr. Bifani will head the Institute research effort and lead the studies which are a first step towards a broader potential collaboration to establish a joint research unit, aiming at collecting and typing Mtb strains in the development of Regma's phage therapy.
Dr. Juan Pablo Bifani has an extensive publication record, particularly in the field of Mtb research.
Dr. Bifani completed his Doctorate in Microbiology (PhD) in the Department of Microbiology, at the Sackler Institute of Graduate Biomedical Sciences, New York University Medical Center, New York, New York. Dr. Bifani's thesis title was "Genetic Analysis of Natural Populations of Mycobacterium tuberculosis Using Molecular Fingerprinting Tools". He completed his Master of Science Degree (Biochemistry) in the Department of Biochemistry at Mahidol University, Bangkok, Thailand, with his thesis "Design, Synthesis and Cloning of Industrial Lipase". Dr. Bifani's Bachelor of Science Degree, was earned through the Department of Chemistry and Biochemistry at the University of Guelph, Guelph, Ontario, Canada.
The Institut Pasteur de Lille is a recognized authority in the field of tuberculosis research and consists of 3 Federative Research Groups and 14 research teams in partnership with INSERM, CNRS, Universities and the Regional Hospital of Lille.
Tuberculosis (TB) is a resurgent problem in industrialized countries. The wide use of antibiotics gave the impression that this was a disease under control. The advent of AIDS and multi-drug resistance has undermined this notion. The increase in TB during the late eighties and early nineties coincided with a rising incidence of AIDS. The immune suppressed AIDS population facilitates the spread of TB. Treatment of TB currently requires a long and comparatively complicated course of antibiotic therapy. The nature of this treatment and the epidemiology of Mycobacterium tuberculosis, the causative agent of tuberculosis, lend themselves to the development of drug resistance. This rising tide of drug resistance and the varying efficacy of available treatments is driving Regma's search for alternative therapies through its novel methods and technologies.
Regma develops novel methods, agents, and technologies for the prevention and treatment of infectious diseases. Regma's overall strategy includes the development of drug systems, which can increase the bioavailability of the drug at a cellular level.
NOTE: Forward-looking statements in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties as discussed and identified from time to time in the Company's public filings which could cause actual results to differ materially from those discussed in the forward-looking statements and from historical results of operations. Readers are cautioned that forward-looking statements are not guarantees of future performance and that actual results might differ materially from those contained in any forward-looking statements. We do not assume the obligation to update any forward-looking statements.
CONTACT: Regma Bio Technologies Limited Investor Relations, 877/792-6688 ir_regma@telus.net or Ron Cooper, 877/692-8288 www.regma.co.uk
SOURCE: Regma Bio Technologies Limited
020619
BW020613
Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .